Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Charles River Laboratories Intl
(NY:
CRL
)
191.19
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Charles River Laboratories Intl
< Previous
1
2
3
4
5
6
7
8
Next >
CRL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors With Losses In Excess of $100K to Inquire About Securities Class Action Investigation – CRL
February 23, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
February 23, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
February 22, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
February 22, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
February 22, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
February 22, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
February 22, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
February 16, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
February 15, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
February 13, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
February 09, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Acquires SAMDI Tech
January 30, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
January 18, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
January 16, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
January 12, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
January 09, 2023
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
December 06, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection
December 01, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Opens Contract Vivarium Space in Chicago, Enhancing Access to AAALAC-Accredited, Turnkey Research Program
November 28, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories to Present at November Investor Conferences
November 14, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Demonstrates Excellence in Advanced Modalities at Neuroscience 2022
November 10, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Announces Cell Therapy Manufacturing Capacity Expansion, Reinforcing Commitment to CDMO Clients
November 07, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Announces Third-Quarter 2022 Results
November 02, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
October 18, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
October 11, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
October 10, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
September 08, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
September 06, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Expands Contract Vivarium Space on West Coast
August 23, 2022
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
August 09, 2022
From
Charles River Laboratories, International Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.